THE WOODLANDS, Texas, Sept. 1 /CNW/ - Berlin Heart Inc. reported today
that it has completed enrollment in Cohort 1 of the Berlin Heart EXCOR(R)
Pediatric IDE Study after having received unconditional approval of the study
from the FDA in November 2008.
The Principal Investigator, Dr. Charles Fraser, Chief of Congenital Heart
Surgery at Texas Children's Hospital and Professor of Surgery and Pediatrics
at Baylor College of Medicine said, "We are very pleased with the progress of
this study. Reaching this extremely important milestone brings us a step
closer to understanding the potential of the EXCOR device as a reliable option
for children with no hope who are dying from heart failure."
The last two patients implanted in this Cohort were implanted at Texas
Children's Hospital in Houston, Texas by Dr. David Morales and at Children's
Hospital of Wisconsin in Milwaukee, Wisconsin by Dr. James Tweddell.
Dr. Johannes Mueller, CEO of Berlin Heart commented, "Berlin Heart is
proud that the EXCOR device is the first ventricular assist device to be
involved in a prospective clinical trial involving the pediatric population.
We are very pleased with the early clinical results of the study and are
excited as this milestone brings us closer to our goal of making this device
more readily available for sick children in the US."
Bob Kroslowitz, Vice President of Clinical Affairs for Berlin Heart said,
"This is an outstanding achievement for the whole team. We especially thank
our study sites, our investigators and most importantly, the families of the
children that have been enrolled in the study. We look forward to compiling
the results and submitting an application to the FDA for approval for this
important group of patients while we continue to enroll additional pediatric
patients into Cohort 2 of the study."
Implants of the EXCOR Pediatric device for Cohort 1 patients are
continuing under a Continued Access Protocol that was recently approved by the
About EXCOR Pediatric
The EXCOR Pediatric ventricular assist device is a pulsatile,
pneumatically driven cardiac support system for critically ill pediatric
patients suffering from severe heart failure. It has been used in more than
600 pediatric patients worldwide ranging from newborns with 2.2 kg body weight
to teenagers. EXCOR Pediatric is currently under clinical investigation for
pediatric patients in USA.
About Berlin Heart
Berlin Heart GmbH is the only company worldwide that develops, produces,
and distributes implantable and external ventricular assist devices for
patients of every age and body size. The company is market leader in Germany
and Europe. The company also manufactures the implantable left ventricular
assist device INCOR(R), which has been designed for long-term application in
adult patients. The longest the device has supported a patient so far is more
than six years. INCOR is not FDA approved, but widely used in Europe.
For further information:
For further information: Linda Buerk, Manager Marketing & PR, Phone:
+49(0)30-8187-2650, Mobile: +49(0)173-629-0803, firstname.lastname@example.org